← Back to headlines
Fortress Biotech's Cyprium Sells PRV for $205 Million
Fortress Biotech's subsidiary, Cyprium Therapeutics, has entered an agreement to sell its Priority Review Voucher (PRV) for $205 million.
24 Feb, 13:53 — 24 Feb, 13:53
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Polish Ministry of Finance Proposes Higher PCC Tax Exemption
5m ago
Watch: Gold rate rises Rs 400 to Rs 1.63 lakh/10g
15m ago
Billionaire Investor Stanley Druckenmiller Eliminated His Fund's Position in Meta Platforms and Piled into Another "Magnificent Seven" Stock That's Been Getting Crushed by the Broader Market
15m ago
Acadia Healthcare Q4 2025 Earnings Preview
16m ago